Literature DB >> 23236230

Role of gastrin-peptides in Barrett's and colorectal carcinogenesis.

Eduardo Chueca1, Angel Lanas, Elena Piazuelo.   

Abstract

Gastrin is the main hormone responsible for the stimulation of gastric acid secretion; in addition, gastrin and its derivatives exert proliferative and antiapoptotic effects on several cell types. Gastrin synthesis and secretion are increased in certain situations, for example, when proton pump inhibitors are used. The impact of sustained hypergastrinemia is currently being investigated. In vitro experiments and animal models have shown that prolonged hypergastrinemia may be related with higher cancer rates; although, this relationship is less clear in human beings. Higher gastrin levels have been shown to cause hyperplasia of several cell types; yet, the risk for developing cancer seems to be the same in normo- and hypergastrinemic patients. Some tumors also produce their own gastrin, which can act in an autocrine manner promoting tumor growth. Certain cancers are extremely dependent on gastrin to proliferate. Initial research focused only on the effects of amidated gastrins, but there has been an interest in intermediates of gastrin in the last few decades. These intermediates aren't biologically inactive; in fact, they may exert greater effects on proliferation and apoptosis than the completely processed forms. In certain gastrin overproduction states, they are the most abundant gastrin peptides secreted. The purpose of this review is to examine the gastrin biosynthesis process and to summarize the results from different studies evaluating the production, levels, and effects of the main forms of gastrin in different overexpression states and their possible relationship with Barrett's and colorectal carcinogenesis.

Entities:  

Keywords:  Barrett’s esophagus; C-terminal flanking peptide; Colorectal cancer; Esophageal adenocarcinoma; Gastrin; Glycine-extended gastrins; Hypergastrinemia; Progastrin; Proton pump inhibitors

Mesh:

Substances:

Year:  2012        PMID: 23236230      PMCID: PMC3516208          DOI: 10.3748/wjg.v18.i45.6560

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  98 in total

1.  Progastrin1-80 stimulates growth of intestinal epithelial cells in vitro via high-affinity binding sites.

Authors:  P Singh; X Lu; S Cobb; B T Miller; N Tarasova; A Varro; A Owlia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-10-16       Impact factor: 4.052

Review 2.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.

Authors:  Navtej S Buttar; Kenneth K Wang; Olga Leontovich; Jay Y Westcott; Rodney J Pacifico; Marlys A Anderson; Krishnawatie K Krishnadath; Lori S Lutzke; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

4.  Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.

Authors:  C Lagorce; F Paraf; D Vidaud; A Couvelard; D Wendum; A Martin; J-F Fléjou
Journal:  Histopathology       Date:  2003-05       Impact factor: 5.087

5.  Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor.

Authors:  Chris R Haigh; Stephen E A Attwood; David G Thompson; Janusz A Jankowski; Chris M Kirton; D Mark Pritchard; Andrea Varro; Rod Dimaline
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

Review 6.  COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.

Authors:  E Piazuelo; P Jimenez; A Lanas
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

7.  Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.

Authors:  Baljeet S Kaur; Niloufar Khamnehei; Mohamed Iravani; Sai S Namburu; Otto Lin; George Triadafilopoulos
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

8.  Precursor peptide progastrin(1-80) reduces apoptosis of intestinal epithelial cells and upregulates cytochrome c oxidase Vb levels and synthesis of ATP.

Authors:  Hai Wu; Azarmidokht Owlia; Pomila Singh
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-07-24       Impact factor: 4.052

9.  The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.

Authors:  Elham Rahme; Alan N Barkun; Youssef Toubouti; Marc Bardou
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

Review 10.  Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.

Authors:  Douglas A Corley; Karla Kerlikowske; Rajiv Verma; Patricia Buffler
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

View more
  7 in total

1.  Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Jian-Xiong Huang; Jian Wu; Guang Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Expression and clinical significance of Sirt1 in colorectal cancer.

Authors:  Deng-Feng Yu; Su-Juan Jiang; Zhi-Peng Pan; Wei-Dong Cheng; Wen-Jun Zhang; Xiao-Kun Yao; Yu-Cheng Li; Yong-Zhi Lun
Journal:  Oncol Lett       Date:  2015-12-01       Impact factor: 2.967

3.  Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance.

Authors:  Yuji Amano; Ryotaro Nakahara; Takafumi Yuki; Daisuke Murakami; Tetsuro Ujihara; Iwaki Tomoyuki; Ryota Sagami; Satoshi Suehiro; Yasushi Katsuyama; Kenji Hayasaka; Hideaki Harada; Yasumasa Tada; Youichi Miyaoka; Hirofumi Fujishiro
Journal:  J Gastroenterol       Date:  2019-06-25       Impact factor: 7.527

4.  Effect of proton pump inhibitors on glycemic control in patients with diabetes.

Authors:  Kohzo Takebayashi; Toshihiko Inukai
Journal:  World J Diabetes       Date:  2015-08-25

5.  Correlation between Helicobacter pylori-associated gastric diseases and colorectal neoplasia.

Authors:  Ying Qing; Min Wang; Ying-Min Lin; Dong Wu; Jing-Yu Zhu; Lang Gao; Yan-Yan Liu; Teng-Fei Yin
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

6.  Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer.

Authors:  Maidina Abuduwaili; Tomoyuki Boda; Masanori Ito; Hidehiko Takigawa; Takahiro Kotachi; Taiji Matsuo; Shiro Oka; Shinji Tanaka
Journal:  Gastroenterol Res Pract       Date:  2022-01-28       Impact factor: 2.260

Review 7.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.